Concomitant Intraductal Papillary Mucinous Neoplasms and Neuroendocrine Tumors of the Pancreas: More than just a Coincidence? Abstract #1930

Introduction: Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic neuroendocrine tumors (pNETs) are rare tumors. Up to now 14 patients with association of endocrine and exocrine neoplasms of the pancreas have been reported in literature: this association is not expected to be frequent
Aim(s): We looked for any common findings between these two entities that could help early recognition and further comprehension of this association
Materials and methods: 6 patients in our clinic suffer from IPMN and concomitant pNET. We collected data about the patients (age, sex, symptoms, medical history, blood chemistry, type of imaging) and about the lesions (classification, dimension, localization, imaging features, fine-needle aspiration (FNA) biopsies results and histology)
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Pablo Cortegoso Valdivia
Keywords: IPMN, NET, pancreas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...
#2273 The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Follow-up after resection of pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence early, as incidence is reported up to 48%.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: M.D. Cansu Genc
#518 CK19 and KIT Immunostaining is a Useful Adjunct to Ki-67-Based Grading of Pancreatic NET: A Study on Matched Cytological and Histological Samples
Introduction: Pancreatic neuroendocrine tumors (NET) are rare neoplasms. Recent evidence suggests that Ki-67 staining predicts their behavior. Even more recently, a prognostic role has been proposed also for CK19 and KIT. This panel might guide patient management. CK19 and KIT have not yet been evaluated on NET on Fine needle aspiration samples (FNAs).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Giancarlo Troncone
Keywords: FNA, pancreas, NET, Ki-67, Kit, CK19
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering